Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Howard Lazarus is now chief medical officer of Altavant Sciences, joining the company from Boehringer Ingelheim Pharmaceuticals as the medical expert/executive director of clinical development and medical affairs.
Alicyn Campbell has been appointed to head of digital health oncology R&D at AstraZeneca. Campbell recently led an oncology patient-centered outcomes research group at Roche/Genentech.
Seth Ettenberg is now the chief scientific officer for BlueRock Therapeutics, joining the firm after previously serving as chief scientific officer of Unum Therapeutics.
Alan Kimura has been appointed to head the rare disease department at CureVac. Recently, Kimura was the chief medical officer at Enzyvant.
Eloxx Pharmaceuticals has named Gregory Williams the firm’s new CEO. Williams most recently served as the company’s chief operating officer. Eloxx has also announced the appointment of Neil Belloff to the role of chief operating officer. Previously, Belloff was the senior corporate counsel at Celgene.
Sridhar Venkatesh has been appointed to the role of managing director and vice president of GlaxoSmithKline India. Venkatesh has held multiple roles at Avalara GlaxoSmithKline India prior to this appointment.
Susan Brisendine has been named vice president of engagement programs at Global Genes, joining the company after serving as the chief architect of the global cell and gene medicine educational program at the ARM Foundation for Cell & Gene Medicine. Global Genes has also appointed Christian Rubio as vice president of strategic advancement. Rubio previously served as vice president of marketing at PlatformQ Health. Pam Rattananont has joined Global Genes as the vice president of development and marketing.
KBI Biopharma has promoted Dirk Lange to the position of CEO. Prior, Lange was the company’s chief operating officer.
Immuno-oncology company Nouscom has named Marina Udier the company’s CEO. Previously, Udier was chief operating officer at Nouscom. Additionally, Nouscom announced the appointment of Patricia Delaite to the role of chief medical officer. Prior to this appointment, Delaite was chief medical officer at AMAL Therapeutics.
Oculis has appointed Marcia de Souza Lima to the role of chief medical officer. Most recently, de Souza Lima served as the vice president and head of global medical affairs for the global ophthalmology franchise at Shire.
Sanjay Sehgal has been named chief of regulatory affairs and quality assurance officer at Rafael Pharmaceuticals, a newly created position within the organization. Previously, Sehgal was senior vice president of regulatory affairs and conformance at Celularity.
Robert Stewart has been appointed CEO of Theramex, replacing Anish Mehta who has stepped down from the position. Stewart was most recently the CEO of Amneal.
Paul Lévesque has been appointed president and CEO of Theratechnologies, replacing newly retired Luc Tanguay. Lévesque will hold his current position of global president of Pfizer’s rare disease division until he assumes his new position at Theratechnologies.
Anirvan Ghosh will now act as UNITY Biotechnology’s CEO, having been tapped from his previous position as senior vice president and head of research and early development at Biogen.